In-vivo half-life and hypoglycemic bioactivity of a fusion protein of exenatide and elastin-based polypeptide from recombinant Saccharomyces cerevisiae

Jung, Su Jin; Nguyen, Ngoc-Thanh Thi; Lee, Sang Ah; Seo, Sung Hwa; Choi, Eui‐Sung; Lee, Hong Weon; Seong, Gi Hun; Bae, Ok Nam; Lee, E.K.

doi:10.1016/j.jbiotec.2019.06.304

Cited by 3 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a chimeric ω-conotoxin MVIIA was conjugated to a trans-activator of transcription (TAT) domain, allowing the chimeric peptide to cross the blood–brain barrier and thus overcome a major obstacle for conotoxin-based therapeutics ( Yu et al, 2019 ). Likewise, the anti-diabetic drug exenatide (a toxin from Heloderma suspectum venom) was linked to elastin to improve stability ( Jung et al, 2019 ). Finally, fusion proteins based on Leiurus quinquestriatus chlorotoxin facilitated drug delivery to glioblastomas ( Kasai et al, 2012 ; Costa et al, 2013 ; Cohen-Inbar and Zaaroor, 2016 ; Cohen et al, 2018 ; Wang et al, 2020b ).…”

Section: How Synthetic Biology Enables Access To Venom Gene Productsmentioning

confidence: 99%

Venom biotechnology: casting light on nature’s deadliest weapons using synthetic biology

Lüddecke

Paas

Harris

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Venoms are complex chemical arsenals that have evolved independently many times in the animal kingdom. Venoms have attracted the interest of researchers because they are an important innovation that has contributed greatly to the evolutionary success of many animals, and their medical relevance offers significant potential for drug discovery. During the last decade, venom research has been revolutionized by the application of systems biology, giving rise to a novel field known as venomics. More recently, biotechnology has also made an increasing impact in this field. Its methods provide the means to disentangle and study venom systems across all levels of biological organization and, given their tremendous impact on the life sciences, these pivotal tools greatly facilitate the coherent understanding of venom system organization, development, biochemistry, and therapeutic activity. Even so, we lack a comprehensive overview of major advances achieved by applying biotechnology to venom systems. This review therefore considers the methods, insights, and potential future developments of biotechnological applications in the field of venom research. We follow the levels of biological organization and structure, starting with the methods used to study the genomic blueprint and genetic machinery of venoms, followed gene products and their functional phenotypes. We argue that biotechnology can answer some of the most urgent questions in venom research, particularly when multiple approaches are combined together, and with other venomics technologies.

show abstract

Section: How Synthetic Biology Enables Access To Venom Gene Productsmentioning

confidence: 99%

Venom biotechnology: casting light on nature’s deadliest weapons using synthetic biology

Lüddecke

Paas

Harris

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers

Cui

Zhao

et al. 2020

Eur J Drug Metab Pharmacokinet

View full text Add to dashboard Cite

Accessible Type 2 diabetes medication through stable expression of Exendin-4 in Saccharomyces cerevisiae

Balius,

Imani,

Petroff

et al. 2024

Front. Syst. Biol.

View full text Add to dashboard Cite

Diabetes mellitus affects roughly one in ten people globally and is the world’s ninth leading cause of death. However, a significant portion of chronic complications that contribute to mortality can be prevented with proper treatment and medication. Glucagon-like peptide 1 receptor agonists, such as Exendin-4, are one of the leading classes of Type 2 diabetes treatments but are prohibitively expensive. In this study, experimental models for recombinant Exendin-4 protein production were designed in both Escherichia coli and Saccharomyces cerevisiae. Protein expression in the chromosomally integrated S. cerevisiae strain was observed at the expected size of Exendin-4 and confirmed by immunoassay. This provides a foundation for the use of this Generally Regarded as Safe organism as an affordable treatment for Type 2 diabetes that can be propagated, prepared, and distributed locally.

show abstract

In-vivo half-life and hypoglycemic bioactivity of a fusion protein of exenatide and elastin-based polypeptide from recombinant Saccharomyces cerevisiae

Cited by 3 publications

References 35 publications

Venom biotechnology: casting light on nature’s deadliest weapons using synthetic biology

Venom biotechnology: casting light on nature’s deadliest weapons using synthetic biology

Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers

Accessible Type 2 diabetes medication through stable expression of Exendin-4 in Saccharomyces cerevisiae

Contact Info

Product

Resources

About